Firm co-founder Dr. Kirsten Grüneberg recently spoke at the 4th IIPLA European Global Pharma IP Summit in London. There, Dr. Grüneberg joined a list of speakers including patent attorneys and practitioners from around to world to discuss the state of IP today in the pharmaceutical industry.

Pharmaceutical companies face an ever-evolving landscape under U.S. patent law, in particular with respect to patent-eligible subject matter. Following recent memoranda from the U.S. Patent and Trademark Office in April and also just days before the summit in June, Dr. Grüneberg provided an explanation of recent developments, practical strategic advice for handling pharmaceutical patent matters in the face of a dynamic situation, and perspective as to the future of subject matter eligibility.

Launched in September 2017, Grüneberg and Myers PLLC is a 100 percent female- and minority-owned international patent firm. With a broad and sophisticated practice, the firm provides a full range of patent support services, including patent prosecution, counseling, post-grant representation, and M&A due diligence to meet the growing and diverse needs of U.S.-based, European, and Asian companies, entrepreneurs, and inventors.